Ocuphire Pharma Inc (OCUP)

NASDAQ
1.900
-0.120(-5.94%)
After Hours
2.050
+0.150(+7.889%)
- Real-time Data
  • Volume:
    286,606
  • Day's Range:
    1.900 - 2.080
  • 52 wk Range:
    1.780 - 6.980

OCUP Overview

Prev. Close
2.02
Day's Range
1.9-2.08
Revenue
590K
Open
2.07
52 wk Range
1.78-6.98
EPS
-1.48
Volume
286,606
Market Cap
38.15M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
196,206
P/E Ratio
-
Beta
0.3
1-Year Change
-58.18%
Shares Outstanding
19,364,367
Next Earnings Date
Aug 11, 2022
What is your sentiment on Ocuphire Pharma?
or
Market is currently closed. Voting is open during market hours.

Ocuphire Pharma Inc Company Profile

Ocuphire Pharma Inc Company Profile

Employees
8

Ocuphire Pharma, Inc. is an ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Nice
    0
    • Analyst Matthew Caufield set a price target of $26 on the stock, outlining four reasons for doing so. The company's shares are currently 38% above Tuesday's close at $4.81 but initially rose to a high of $5.50. The first of the four reasons for the rating is Ocuphire's phase 3 MIRA-2 trial's positive topline results for Nyxol. The analyst said that it presents an "opportune timing to get into the name prior to further program validation," which it expects in the near term. He also said a key differentiation of using Nyxol was another positive for the stock, adding that Ocuphire's APX3330 treatment for diabetic retinopathy is undervalued. "With Ocuphire completing a reverse merger with legacy oncology platform Rexahn Pharmaceuticals, and listing on NASDAQ in November 2020, we maintain invest
      0
      • BLIN is next MRIN
        0
        • I like $12. Holding until then at least. Good company.
          0
          • Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
            1
            • Any target price?
              0